We recommend

  1. Biotech accelerator BioMotiv, NYU unveil a new spinoff for inflammatory disease treatments
    MedCity News
  2. With $46M in tow, accelerator/investor BioMotiv puts to work a new model for drug development
    MedCity News
  3. There’s a new twist to early stage drug discovery financing: technology without the team (video)
    MedCity News
  4. BioAtla-BioMotiv licensing deal results in new biotech startup to develop IBD, cancer drugs
    MedCity News
  5. With $46M in tow, accelerator/investor BioMotiv puts to work a new model for drug development - MedCity News
    MedCity News

 

  1. NCET2 Panel Says Angel Investors Often Reluctant to Span Spinout Funding Gap
    GenomeWeb
  2. Cornell Medical Debuts ‘Startup Boot Camp’ To Educate, Motivate Would-Be Entrepreneurs
    GenomeWeb
  3. Dx Executives Hopeful for Improved Regulation, More Product Development Funding
    360Dx
  4. Patent nonsense: Evidence tells of an industry out of social control
    Henry Mintzberg, CMAJ
  5. Drug companies should target drug plans, rather than physicians, consultant says
    Ann Silversides, CMAJ
Powered by TrendMD